Keywords: GlaxoSmithKline, San Raffaele Telethon Institute for Gener Theapy, Rare disease strategy, Genetic disorders
GlaxoSmithKline in R&D pact with two Italian groups for rare genetic disorders; outlines rare disease strategy
Article | 19 October 2010
UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) yesterday revealed a new strategic alliance with two Italian groups to research and develop ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
